Dissolution of radiolucent cholesterol gallstones in patients with a functioning gallbladder (stones < /15 /mm)
Cholestatic liver disorders including compensated primary biliary cirrhosis and cholestasis of pregnancy
Gallstone dissolution: Approx. /10 /mg/kg/day, e.g. ~2 capsules/day if ≤ /60 /kg; up to ~5–6 capsules/day for >110 /kg, divided into two or more doses. Treatment duration typically spans 6–24 months
Cholestatic liver disease: 10–15 /mg/kg/day; monitor according to weight-based dosing similar to gallstone regimen
Administration: Swallow whole with food and some liquid to aid absorption
Contraindicated in:
Acute cholecystitis or bile duct inflammation
Obstructed biliary tract or calcified (radiopaque) gallstones
Impaired gallbladder contractility or frequent biliary colic
Hypersensitivity to UDCA or formulation excipients
Monitoring:
Liver enzymes (AST, ALT, γ GT) every 4 weeks during first 3 months, then every 3 months after
Reassess gallbladder integrity via ultrasound 6–10 months into treatment to verify functionality and stone status
Women of childbearing potential should use effective contraception; avoid use in pregnancy and lactation unless clearly necessary
Common adverse effects:
Gastrointestinal: soft or loose stools, diarrhea, nausea, vomiting
Pruritus (itching), rash, hair loss (less common)
Drug interactions:
Reduced effectiveness: cholestyramine, colestipol, antacids containing Al(OH) or smectite, ciprofloxacin, dapsone, nitrendipine
Increased blood levels: ciclosporin, possibly rosuvastatin
Skip the missed dose if it's nearly time for your next scheduled dose — do not double the next one
Stable at room temperature; no special storage requirements. Keep in blisters/cartons as supplied
Malaysia
